 | • レポートコード：MRC2-11QY03559 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、151ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：化学・材料 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はCディフィシル感染症治療薬のグローバル市場について調査・分析したレポートです。種類別（メトロニダゾール、バンコマイシン、フィダキソマイシン、その他）市場規模、用途別（前処理、中期処理、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別Cディフィシル感染症治療薬の競争状況、市場シェア ・世界のCディフィシル感染症治療薬市場：種類別市場規模 2015年-2020年（メトロニダゾール、バンコマイシン、フィダキソマイシン、その他） ・世界のCディフィシル感染症治療薬市場：種類別市場規模予測 2021年-2026年（メトロニダゾール、バンコマイシン、フィダキソマイシン、その他） ・世界のCディフィシル感染症治療薬市場：用途別市場規模 2015年-2020年（前処理、中期処理、その他） ・世界のCディフィシル感染症治療薬市場：用途別市場規模予測 2021年-2026年（前処理、中期処理、その他） ・北米のCディフィシル感染症治療薬市場分析：米国、カナダ ・ヨーロッパのCディフィシル感染症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのCディフィシル感染症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のCディフィシル感染症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのCディフィシル感染症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Merck、Astellas、Eli Lilly、ANI Pharmaceutical、Flynn Pharma、Aspen Pharmacare、Akorn、Merus labs、Pfizer、AstraZeneca、Strides、Sanofi、Fresenius、Xellia、Zhejiang Medicine、Lupin ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global C Difficile Infection Drug Market
The global C Difficile Infection Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global C Difficile Infection Drug Scope and Market Size
C Difficile Infection Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global C Difficile Infection Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the C Difficile Infection Drug market is segmented into
Metronidazole
Vancomycin
Fidaxomycin
Others
Segment by Application, the C Difficile Infection Drug market is segmented into
Pre-treatment
Mid-term treatment
Others
Regional and Country-level Analysis
The C Difficile Infection Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the C Difficile Infection Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and C Difficile Infection Drug Market Share Analysis
C Difficile Infection Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in C Difficile Infection Drug business, the date to enter into the C Difficile Infection Drug market, C Difficile Infection Drug product introduction, recent developments, etc.
The major vendors covered:
Merck
Astellas
Eli Lilly
ANI Pharmaceutical
Flynn Pharma
Aspen Pharmacare
Akorn
Merus labs
Pfizer
AstraZeneca
Strides
Sanofi
Fresenius
Xellia
Zhejiang Medicine
Lupin
1 Study Coverage
1.1 C Difficile Infection Drug Product Introduction
1.2 Market Segments
1.3 Key C Difficile Infection Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global C Difficile Infection Drug Market Size Growth Rate by Type
1.4.2 Metronidazole
1.4.3 Vancomycin
1.4.4 Fidaxomycin
1.4.5 Others
1.5 Market by Application
1.5.1 Global C Difficile Infection Drug Market Size Growth Rate by Application
1.5.2 Pre-treatment
1.5.3 Mid-term treatment
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global C Difficile Infection Drug Market Size, Estimates and Forecasts
2.1.1 Global C Difficile Infection Drug Revenue 2015-2026
2.1.2 Global C Difficile Infection Drug Sales 2015-2026
2.2 Global C Difficile Infection Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global C Difficile Infection Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global C Difficile Infection Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global C Difficile Infection Drug Competitor Landscape by Players
3.1 C Difficile Infection Drug Sales by Manufacturers
3.1.1 C Difficile Infection Drug Sales by Manufacturers (2015-2020)
3.1.2 C Difficile Infection Drug Sales Market Share by Manufacturers (2015-2020)
3.2 C Difficile Infection Drug Revenue by Manufacturers
3.2.1 C Difficile Infection Drug Revenue by Manufacturers (2015-2020)
3.2.2 C Difficile Infection Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global C Difficile Infection Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by C Difficile Infection Drug Revenue in 2019
3.2.5 Global C Difficile Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 C Difficile Infection Drug Price by Manufacturers
3.4 C Difficile Infection Drug Manufacturing Base Distribution, Product Types
3.4.1 C Difficile Infection Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers C Difficile Infection Drug Product Type
3.4.3 Date of International Manufacturers Enter into C Difficile Infection Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global C Difficile Infection Drug Market Size by Type (2015-2020)
4.1.1 Global C Difficile Infection Drug Sales by Type (2015-2020)
4.1.2 Global C Difficile Infection Drug Revenue by Type (2015-2020)
4.1.3 C Difficile Infection Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global C Difficile Infection Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global C Difficile Infection Drug Sales Forecast by Type (2021-2026)
4.2.2 Global C Difficile Infection Drug Revenue Forecast by Type (2021-2026)
4.2.3 C Difficile Infection Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global C Difficile Infection Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global C Difficile Infection Drug Market Size by Application (2015-2020)
5.1.1 Global C Difficile Infection Drug Sales by Application (2015-2020)
5.1.2 Global C Difficile Infection Drug Revenue by Application (2015-2020)
5.1.3 C Difficile Infection Drug Price by Application (2015-2020)
5.2 C Difficile Infection Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global C Difficile Infection Drug Sales Forecast by Application (2021-2026)
5.2.2 Global C Difficile Infection Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global C Difficile Infection Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America C Difficile Infection Drug by Country
6.1.1 North America C Difficile Infection Drug Sales by Country
6.1.2 North America C Difficile Infection Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America C Difficile Infection Drug Market Facts & Figures by Type
6.3 North America C Difficile Infection Drug Market Facts & Figures by Application
7 Europe
7.1 Europe C Difficile Infection Drug by Country
7.1.1 Europe C Difficile Infection Drug Sales by Country
7.1.2 Europe C Difficile Infection Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe C Difficile Infection Drug Market Facts & Figures by Type
7.3 Europe C Difficile Infection Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific C Difficile Infection Drug by Region
8.1.1 Asia Pacific C Difficile Infection Drug Sales by Region
8.1.2 Asia Pacific C Difficile Infection Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific C Difficile Infection Drug Market Facts & Figures by Type
8.3 Asia Pacific C Difficile Infection Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America C Difficile Infection Drug by Country
9.1.1 Latin America C Difficile Infection Drug Sales by Country
9.1.2 Latin America C Difficile Infection Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America C Difficile Infection Drug Market Facts & Figures by Type
9.3 Central & South America C Difficile Infection Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa C Difficile Infection Drug by Country
10.1.1 Middle East and Africa C Difficile Infection Drug Sales by Country
10.1.2 Middle East and Africa C Difficile Infection Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 UAE
10.2 Middle East and Africa C Difficile Infection Drug Market Facts & Figures by Type
10.3 Middle East and Africa C Difficile Infection Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Description and Business Overview
11.1.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Merck C Difficile Infection Drug Products Offered
11.1.5 Merck Related Developments
11.2 Astellas
11.2.1 Astellas Corporation Information
11.2.2 Astellas Description and Business Overview
11.2.3 Astellas Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Astellas C Difficile Infection Drug Products Offered
11.2.5 Astellas Related Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Corporation Information
11.3.2 Eli Lilly Description and Business Overview
11.3.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Eli Lilly C Difficile Infection Drug Products Offered
11.3.5 Eli Lilly Related Developments
11.4 ANI Pharmaceutical
11.4.1 ANI Pharmaceutical Corporation Information
11.4.2 ANI Pharmaceutical Description and Business Overview
11.4.3 ANI Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.4.4 ANI Pharmaceutical C Difficile Infection Drug Products Offered
11.4.5 ANI Pharmaceutical Related Developments
11.5 Flynn Pharma
11.5.1 Flynn Pharma Corporation Information
11.5.2 Flynn Pharma Description and Business Overview
11.5.3 Flynn Pharma Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Flynn Pharma C Difficile Infection Drug Products Offered
11.5.5 Flynn Pharma Related Developments
11.6 Aspen Pharmacare
11.6.1 Aspen Pharmacare Corporation Information
11.6.2 Aspen Pharmacare Description and Business Overview
11.6.3 Aspen Pharmacare Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Aspen Pharmacare C Difficile Infection Drug Products Offered
11.6.5 Aspen Pharmacare Related Developments
11.7 Akorn
11.7.1 Akorn Corporation Information
11.7.2 Akorn Description and Business Overview
11.7.3 Akorn Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Akorn C Difficile Infection Drug Products Offered
11.7.5 Akorn Related Developments
11.8 Merus labs
11.8.1 Merus labs Corporation Information
11.8.2 Merus labs Description and Business Overview
11.8.3 Merus labs Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Merus labs C Difficile Infection Drug Products Offered
11.8.5 Merus labs Related Developments
11.9 Pfizer
11.9.1 Pfizer Corporation Information
11.9.2 Pfizer Description and Business Overview
11.9.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Pfizer C Difficile Infection Drug Products Offered
11.9.5 Pfizer Related Developments
11.10 AstraZeneca
11.10.1 AstraZeneca Corporation Information
11.10.2 AstraZeneca Description and Business Overview
11.10.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.10.4 AstraZeneca C Difficile Infection Drug Products Offered
11.10.5 AstraZeneca Related Developments
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Description and Business Overview
11.1.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Merck C Difficile Infection Drug Products Offered
11.1.5 Merck Related Developments
11.12 Sanofi
11.12.1 Sanofi Corporation Information
11.12.2 Sanofi Description and Business Overview
11.12.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Sanofi Products Offered
11.12.5 Sanofi Related Developments
11.13 Fresenius
11.13.1 Fresenius Corporation Information
11.13.2 Fresenius Description and Business Overview
11.13.3 Fresenius Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Fresenius Products Offered
11.13.5 Fresenius Related Developments
11.14 Xellia
11.14.1 Xellia Corporation Information
11.14.2 Xellia Description and Business Overview
11.14.3 Xellia Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Xellia Products Offered
11.14.5 Xellia Related Developments
11.15 Zhejiang Medicine
11.15.1 Zhejiang Medicine Corporation Information
11.15.2 Zhejiang Medicine Description and Business Overview
11.15.3 Zhejiang Medicine Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Zhejiang Medicine Products Offered
11.15.5 Zhejiang Medicine Related Developments
11.16 Lupin
11.16.1 Lupin Corporation Information
11.16.2 Lupin Description and Business Overview
11.16.3 Lupin Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Lupin Products Offered
11.16.5 Lupin Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 C Difficile Infection Drug Market Estimates and Projections by Region
12.1.1 Global C Difficile Infection Drug Sales Forecast by Regions 2021-2026
12.1.2 Global C Difficile Infection Drug Revenue Forecast by Regions 2021-2026
12.2 North America C Difficile Infection Drug Market Size Forecast (2021-2026)
12.2.1 North America: C Difficile Infection Drug Sales Forecast (2021-2026)
12.2.2 North America: C Difficile Infection Drug Revenue Forecast (2021-2026)
12.2.3 North America: C Difficile Infection Drug Market Size Forecast by Country (2021-2026)
12.3 Europe C Difficile Infection Drug Market Size Forecast (2021-2026)
12.3.1 Europe: C Difficile Infection Drug Sales Forecast (2021-2026)
12.3.2 Europe: C Difficile Infection Drug Revenue Forecast (2021-2026)
12.3.3 Europe: C Difficile Infection Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific C Difficile Infection Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: C Difficile Infection Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: C Difficile Infection Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: C Difficile Infection Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America C Difficile Infection Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: C Difficile Infection Drug Sales Forecast (2021-2026)
12.5.2 Latin America: C Difficile Infection Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: C Difficile Infection Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa C Difficile Infection Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: C Difficile Infection Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: C Difficile Infection Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: C Difficile Infection Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key C Difficile Infection Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 C Difficile Infection Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. C Difficile Infection Drug Market Segments
Table 2. Ranking of Global Top C Difficile Infection Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global C Difficile Infection Drug Market Size Growth Rate by Type 2020-2026 (Kiloton) & (US$ Million)
Table 4. Major Manufacturers of Metronidazole
Table 5. Major Manufacturers of Vancomycin
Table 6. Major Manufacturers of Fidaxomycin
Table 7. Major Manufacturers of Others
Table 8. Global C Difficile Infection Drug Market Size Growth Rate by Application 2020-2026 (Kiloton)
Table 9. Global C Difficile Infection Drug Market Size by Region (Kiloton) & (US$ Million): 2020 VS 2026
Table 10. Global C Difficile Infection Drug Sales by Regions 2015-2020 (Kiloton)
Table 11. Global C Difficile Infection Drug Sales Market Share by Regions (2015-2020)
Table 12. Global C Difficile Infection Drug Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global C Difficile Infection Drug Sales by Manufacturers (2015-2020) (Kiloton)
Table 14. Global C Difficile Infection Drug Sales Share by Manufacturers (2015-2020)
Table 15. Global C Difficile Infection Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global C Difficile Infection Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in C Difficile Infection Drug as of 2019)
Table 17. C Difficile Infection Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. C Difficile Infection Drug Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers C Difficile Infection Drug Price (2015-2020) (US$/Ton)
Table 20. C Difficile Infection Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers C Difficile Infection Drug Product Type
Table 22. Date of International Manufacturers Enter into C Difficile Infection Drug Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global C Difficile Infection Drug Sales by Type (2015-2020) (Kiloton)
Table 25. Global C Difficile Infection Drug Sales Share by Type (2015-2020)
Table 26. Global C Difficile Infection Drug Revenue by Type (2015-2020) (US$ Million)
Table 27. Global C Difficile Infection Drug Revenue Share by Type (2015-2020)
Table 28. C Difficile Infection Drug Average Selling Price (ASP) by Type 2015-2020 (US$/Ton)
Table 29. Global C Difficile Infection Drug Sales by Application (2015-2020) (Kiloton)
Table 30. Global C Difficile Infection Drug Sales Share by Application (2015-2020)
Table 31. North America C Difficile Infection Drug Sales by Country (2015-2020) (Kiloton)
Table 32. North America C Difficile Infection Drug Sales Market Share by Country (2015-2020)
Table 33. North America C Difficile Infection Drug Revenue by Country (2015-2020) (US$ Million)
Table 34. North America C Difficile Infection Drug Revenue Market Share by Country (2015-2020)
Table 35. North America C Difficile Infection Drug Sales by Type (2015-2020) (Kiloton)
Table 36. North America C Difficile Infection Drug Sales Market Share by Type (2015-2020)
Table 37. North America C Difficile Infection Drug Sales by Application (2015-2020) (Kiloton)
Table 38. North America C Difficile Infection Drug Sales Market Share by Application (2015-2020)
Table 39. Europe C Difficile Infection Drug Sales by Country (2015-2020) (Kiloton)
Table 40. Europe C Difficile Infection Drug Sales Market Share by Country (2015-2020)
Table 41. Europe C Difficile Infection Drug Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe C Difficile Infection Drug Revenue Market Share by Country (2015-2020)
Table 43. Europe C Difficile Infection Drug Sales by Type (2015-2020) (Kiloton)
Table 44. Europe C Difficile Infection Drug Sales Market Share by Type (2015-2020)
Table 45. Europe C Difficile Infection Drug Sales by Application (2015-2020) (Kiloton)
Table 46. Europe C Difficile Infection Drug Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific C Difficile Infection Drug Sales by Region (2015-2020) (Kiloton)
Table 48. Asia Pacific C Difficile Infection Drug Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific C Difficile Infection Drug Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific C Difficile Infection Drug Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific C Difficile Infection Drug Sales by Type (2015-2020) (Kiloton)
Table 52. Asia Pacific C Difficile Infection Drug Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific C Difficile Infection Drug Sales by Application (2015-2020) (Kiloton)
Table 54. Asia Pacific C Difficile Infection Drug Sales Market Share by Application (2015-2020)
Table 55. Latin America C Difficile Infection Drug Sales by Country (2015-2020) (Kiloton)
Table 56. Latin America C Difficile Infection Drug Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa C Difficile Infection Drug Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America C Difficile Infection Drug Revenue Market Share by Country (2015-2020)
Table 59. Latin America C Difficile Infection Drug Sales by Type (2015-2020) (Kiloton)
Table 60. Latin America C Difficile Infection Drug Sales Market Share by Type (2015-2020)
Table 61. Latin America C Difficile Infection Drug Sales by Application (2015-2020) (Kiloton)
Table 62. Latin America C Difficile Infection Drug Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa C Difficile Infection Drug Sales by Country (2015-2020) (Kiloton)
Table 64. Middle East and Africa C Difficile Infection Drug Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa C Difficile Infection Drug Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa C Difficile Infection Drug Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa C Difficile Infection Drug Sales by Type (2015-2020) (Kiloton)
Table 68. Middle East and Africa C Difficile Infection Drug Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa C Difficile Infection Drug Sales by Application (2015-2020) (Kiloton)
Table 70. Middle East and Africa C Difficile Infection Drug Sales Market Share by Application (2015-2020)
Table 71. Merck Corporation Information
Table 72. Merck Description and Major Businesses
Table 73. Merck C Difficile Infection Drug Production (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 74. Merck Product
Table 75. Merck Recent Development
Table 76. Astellas Corporation Information
Table 77. Astellas Description and Major Businesses
Table 78. Astellas C Difficile Infection Drug Production (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 79. Astellas Product
Table 80. Astellas Recent Development
Table 81. Eli Lilly Corporation Information
Table 82. Eli Lilly Description and Major Businesses
Table 83. Eli Lilly C Difficile Infection Drug Production (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 84. Eli Lilly Product
Table 85. Eli Lilly Recent Development
Table 86. ANI Pharmaceutical Corporation Information
Table 87. ANI Pharmaceutical Description and Major Businesses
Table 88. ANI Pharmaceutical C Difficile Infection Drug Production (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 89. ANI Pharmaceutical Product
Table 90. ANI Pharmaceutical Recent Development
Table 91. Flynn Pharma Corporation Information
Table 92. Flynn Pharma Description and Major Businesses
Table 93. Flynn Pharma C Difficile Infection Drug Production (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 94. Flynn Pharma Product
Table 95. Flynn Pharma Recent Development
Table 96. Aspen Pharmacare Corporation Information
Table 97. Aspen Pharmacare Description and Major Businesses
Table 98. Aspen Pharmacare C Difficile Infection Drug Production (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 99. Aspen Pharmacare Product
Table 100. Aspen Pharmacare Recent Development
Table 101. Akorn Corporation Information
Table 102. Akorn Description and Major Businesses
Table 103. Akorn C Difficile Infection Drug Production (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 104. Akorn Product
Table 105. Akorn Recent Development
Table 106. Merus labs Corporation Information
Table 107. Merus labs Description and Major Businesses
Table 108. Merus labs C Difficile Infection Drug Production (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 109. Merus labs Product
Table 110. Merus labs Recent Development
Table 111. Pfizer Corporation Information
Table 112. Pfizer Description and Major Businesses
Table 113. Pfizer C Difficile Infection Drug Production (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 114. Pfizer Product
Table 115. Pfizer Recent Development
Table 116. AstraZeneca Corporation Information
Table 117. AstraZeneca Description and Major Businesses
Table 118. AstraZeneca C Difficile Infection Drug Production (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 119. AstraZeneca Product
Table 120. AstraZeneca Recent Development
Table 121. Strides Corporation Information
Table 122. Strides Description and Major Businesses
Table 123. Strides C Difficile Infection Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 124. Strides Product
Table 125. Strides Recent Development
Table 126. Sanofi Corporation Information
Table 127. Sanofi Description and Major Businesses
Table 128. Sanofi C Difficile Infection Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 129. Sanofi Product
Table 130. Sanofi Recent Development
Table 131. Fresenius Corporation Information
Table 132. Fresenius Description and Major Businesses
Table 133. Fresenius C Difficile Infection Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 134. Fresenius Product
Table 135. Fresenius Recent Development
Table 136. Xellia Corporation Information
Table 137. Xellia Description and Major Businesses
Table 138. Xellia C Difficile Infection Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 139. Xellia Product
Table 140. Xellia Recent Development
Table 141. Zhejiang Medicine Corporation Information
Table 142. Zhejiang Medicine Description and Major Businesses
Table 143. Zhejiang Medicine C Difficile Infection Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 144. Zhejiang Medicine Product
Table 145. Zhejiang Medicine Recent Development
Table 146. Lupin Corporation Information
Table 147. Lupin Description and Major Businesses
Table 148. Lupin C Difficile Infection Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2015-2020)
Table 149. Lupin Product
Table 150. Lupin Recent Development
Table 151. Global C Difficile Infection Drug Sales Forecast by Regions (2021-2026) (Kiloton)
Table 152. Global C Difficile Infection Drug Sales Market Share Forecast by Regions (2021-2026)
Table 153. Global C Difficile Infection Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 154. Global C Difficile Infection Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 155. North America: C Difficile Infection Drug Sales Forecast by Country (2021-2026) (Kiloton)
Table 156. North America: C Difficile Infection Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 157. Europe: C Difficile Infection Drug Sales Forecast by Country (2021-2026) (Kiloton)
Table 158. Europe: C Difficile Infection Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 159. Asia Pacific: C Difficile Infection Drug Sales Forecast by Region (2021-2026) (Kiloton)
Table 160. Asia Pacific: C Difficile Infection Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 161. Latin America: C Difficile Infection Drug Sales Forecast by Country (2021-2026) (Kiloton)
Table 162. Latin America: C Difficile Infection Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 163. Middle East and Africa: C Difficile Infection Drug Sales Forecast by Country (2021-2026) (Kiloton)
Table 164. Middle East and Africa: C Difficile Infection Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 165. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 166. Key Challenges
Table 167. Market Risks
Table 168. Main Points Interviewed from Key C Difficile Infection Drug Players
Table 169. C Difficile Infection Drug Customers List
Table 170. C Difficile Infection Drug Distributors List
Table 171. Research Programs/Design for This Report
Table 172. Key Data Information from Secondary Sources
Table 173. Key Data Information from Primary Sources
List of Figures
Figure 1. C Difficile Infection Drug Product Picture
Figure 2. Global C Difficile Infection Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Metronidazole Product Picture
Figure 4. Vancomycin Product Picture
Figure 5. Fidaxomycin Product Picture
Figure 6. Others Product Picture
Figure 7. Global C Difficile Infection Drug Sales Market Share by Application in 2020 & 2026
Figure 8. Pre-treatment
Figure 9. Mid-term treatment
Figure 10. Others
Figure 11. C Difficile Infection Drug Report Years Considered
Figure 12. Global C Difficile Infection Drug Market Size 2015-2026 (US$ Million)
Figure 13. Global C Difficile Infection Drug Sales 2015-2026 (Kiloton)
Figure 14. Global C Difficile Infection Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global C Difficile Infection Drug Sales Market Share by Region (2015-2020)
Figure 16. Global C Difficile Infection Drug Sales Market Share by Region in 2019
Figure 17. Global C Difficile Infection Drug Revenue Market Share by Region (2015-2020)
Figure 18. Global C Difficile Infection Drug Revenue Market Share by Region in 2019
Figure 19. Global C Difficile Infection Drug Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by C Difficile Infection Drug Revenue in 2019
Figure 21. C Difficile Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global C Difficile Infection Drug Sales Market Share by Type (2015-2020)
Figure 23. Global C Difficile Infection Drug Sales Market Share by Type in 2019
Figure 24. Global C Difficile Infection Drug Revenue Market Share by Type (2015-2020)
Figure 25. Global C Difficile Infection Drug Revenue Market Share by Type in 2019
Figure 26. Global C Difficile Infection Drug Market Share by Price Range (2015-2020)
Figure 27. Global C Difficile Infection Drug Sales Market Share by Application (2015-2020)
Figure 28. Global C Difficile Infection Drug Sales Market Share by Application in 2019
Figure 29. Global C Difficile Infection Drug Revenue Market Share by Application (2015-2020)
Figure 30. Global C Difficile Infection Drug Revenue Market Share by Application in 2019
Figure 31. North America C Difficile Infection Drug Sales Growth Rate 2015-2020 (Kiloton)
Figure 32. North America C Difficile Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America C Difficile Infection Drug Sales Market Share by Country in 2019
Figure 34. North America C Difficile Infection Drug Revenue Market Share by Country in 2019
Figure 35. U.S. C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 36. U.S. C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 38. Canada C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America C Difficile Infection Drug Market Share by Type in 2019
Figure 40. North America C Difficile Infection Drug Market Share by Application in 2019
Figure 41. Europe C Difficile Infection Drug Sales Growth Rate 2015-2020 (Kiloton)
Figure 42. Europe C Difficile Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe C Difficile Infection Drug Sales Market Share by Country in 2019
Figure 44. Europe C Difficile Infection Drug Revenue Market Share by Country in 2019
Figure 45. Germany C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 46. Germany C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 48. France C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 50. U.K. C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 52. Italy C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 54. Russia C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe C Difficile Infection Drug Market Share by Type in 2019
Figure 56. Europe C Difficile Infection Drug Market Share by Application in 2019
Figure 57. Asia Pacific C Difficile Infection Drug Sales Growth Rate 2015-2020 (Kiloton)
Figure 58. Asia Pacific C Difficile Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific C Difficile Infection Drug Sales Market Share by Region in 2019
Figure 60. Asia Pacific C Difficile Infection Drug Revenue Market Share by Region in 2019
Figure 61. China C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 62. China C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 64. Japan C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 66. South Korea C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 68. India C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 70. Australia C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 72. Taiwan C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 74. Indonesia C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 76. Thailand C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 78. Malaysia C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 80. Philippines C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 82. Vietnam C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific C Difficile Infection Drug Market Share by Type in 2019
Figure 84. Asia Pacific C Difficile Infection Drug Market Share by Application in 2019
Figure 85. Latin America C Difficile Infection Drug Sales Growth Rate 2015-2020 (Kiloton)
Figure 86. Latin America C Difficile Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America C Difficile Infection Drug Sales Market Share by Country in 2019
Figure 88. Latin America C Difficile Infection Drug Revenue Market Share by Country in 2019
Figure 89. Mexico C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 90. Mexico C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 92. Brazil C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 94. Argentina C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America C Difficile Infection Drug Market Share by Type in 2019
Figure 96. Latin America C Difficile Infection Drug Market Share by Application in 2019
Figure 97. Middle East and Africa C Difficile Infection Drug Sales Growth Rate 2015-2020 (Kiloton)
Figure 98. Middle East and Africa C Difficile Infection Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa C Difficile Infection Drug Sales Market Share by Country in 2019
Figure 100. Middle East and Africa C Difficile Infection Drug Revenue Market Share by Country in 2019
Figure 101. Turkey C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 102. Turkey C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 104. Saudi Arabia C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. UAE C Difficile Infection Drug Sales Growth Rate (2015-2020) (Kiloton)
Figure 106. UAE C Difficile Infection Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa C Difficile Infection Drug Market Share by Type in 2019
Figure 108. Middle East and Africa C Difficile Infection Drug Market Share by Application in 2019
Figure 109. North America C Difficile Infection Drug Sales Growth Rate Forecast (2021-2026) (Kiloton)
Figure 110. North America C Difficile Infection Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe C Difficile Infection Drug Sales Growth Rate Forecast (2021-2026) (Kiloton)
Figure 112. Europe C Difficile Infection Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific C Difficile Infection Drug Sales Growth Rate Forecast (2021-2026) (Kiloton)
Figure 114. Asia Pacific C Difficile Infection Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America C Difficile Infection Drug Sales Growth Rate Forecast (2021-2026) (Kiloton)
Figure 116. Latin America C Difficile Infection Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa C Difficile Infection Drug Sales Growth Rate Forecast (2021-2026) (Kiloton)
Figure 118. Middle East and Africa C Difficile Infection Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
クロストリジウム・ディフィシル感染症治療の世界市場（～2026年） Clostridium difficile is one of the most common hospital acquired infections and in the last decade, there has been a notable increase in the incidence of clostridium difficile infection as well as the severity of the infection owing to recurrence and antibiotic resistance. Disproportionately higher…- 尿路感染症治療の世界市場（～2026年） Urinary tract infection (UTI) is a common infections of the urinary tract, which consists of the kidneys, ureters, bladder, urethra or prostate gland. This trend of increment in the prevalence rate of diabetes among adults is expected to continue during the forecast period. Therefore, with increasin…
- ジカウイルス感染症治療薬の世界市場（～2026年） It is used to treat various uncomfortable symptoms caused by zika virus infection. Market Analysis and Insights: Global Zika Virus Infection Drug Market The global Zika Virus Infection Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during…
- 耳感染症治療の世界市場（～2026年） An ear infection occurs due to invasion by bacteria or virus causing pain, inflammation and fluid build-up in the ear. Most ear infections are acute but chronic ear infections can cause permanent damage to the middle and inner ear. Eustachian tubes, small tubes running from ear to the back of the th…
- 下気道感染症治療の世界市場（～2026年） The infection below the level of larynx is said to be lower respiratory tract infection. Many a times, lower respiratory tract infection is called pneumonia. These infection are not defined uniformly, but epidemiologically, these infections includes flu, bronchitis, bronchiolitis, and pneumonia. The…